Business Context and Reporting Period
This Form 8-K was filed by Pluristem Therapeutics Inc. on January 10, 2022, reporting an event that occurred on January 5, 2022. The filing details the entry into a material definitive agreement to establish a joint venture, Plurinuva Ltd. (NewCo), with Tnuva Food Industries – Agricultural Cooperative in Israel Ltd. The joint venture is focused on the development, manufacturing, and commercialization of cultured meat products.
Key Financial Metrics and Transaction Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for Pluristem Therapeutics Inc. as this is a current report regarding a specific corporate event rather than a periodic financial statement. However, the following financial terms regarding the joint venture transaction are disclosed:
- Investment Amount: Tnuva is investing $7,500,000 in cash.
- Equity Stake: In exchange for the investment, Tnuva will receive 187,500 ordinary shares of NewCo, representing 15.79% of its share capital at closing.
- First Warrant: Tnuva receives a warrant to purchase up to 125,000 ordinary shares at an exercise price of $40.00 per share. The term is six months from closing or until an IPO/acquisition/financing round, whichever is earlier.
- Second Warrant: Issued six months post-closing (if the First Warrant is unexpired and partially exercised), allowing Tnuva to purchase shares at $76.00 per share. The aggregate purchase price for this warrant equals 200% of the remaining balance of the First Warrant's aggregate exercise price.
- Royalties: NewCo will pay Pluristem royalties in the mid-single digits for the use of licensed technology.
Material Changes and Agreements
The primary material change is the formation of the joint venture and the execution of three key agreements:
- Share Purchase Agreement (SPA): Governs Tnuva's investment and warrant structure.
- Technology License Agreement: Pluristem grants NewCo an exclusive, royalty-bearing, perpetual, worldwide license for cultured meat technology. Conversely, NewCo grants Pluristem a royalty-free license to use improvements made to the technology outside the cultured meat field.
- Transitional Services Agreement: Pluristem will provide transitional services to NewCo on a cost basis for an initial 18-month term, extendable by six months.
- Commercialization Rights: Tnuva will receive exclusive marketing, distribution, and sale rights for the products in Israel, subject to milestones. NewCo retains exclusive worldwide rights outside of Israel.
Guidance, Risks, and Contingencies
Conditions Precedent: The consummation of the transaction is subject to customary conditions, specifically including the approval of the Israeli Innovation Authority.
Future Opportunities: If Pluristem decides to use its technology for cultured milk or fish products, Tnuva has the right to participate in the formation of additional separate joint ventures for those products for a period of seven years following the closing date.
Risks: The filing does not explicitly list risk factors beyond the standard condition precedent regarding regulatory approval. The success of the venture depends on the development of the technology and the achievement of commercialization milestones.
Key Facts for Investor Verification
- Verify the status of the Israeli Innovation Authority approval required to close the transaction.
- Confirm the final valuation of NewCo implied by the $7.5 million investment for a 15.79% stake.
- Monitor the execution of the Technology License Agreement and the specific definition of "mid-single digits" for royalty payments.
- Track the milestones required for Tnuva to maintain exclusivity in the Israeli market.
- Assess the potential impact of the joint venture on Pluristem's existing cash position and future capital requirements.